KD025 Hepatic Impairment Study With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This is a study to characterize the pharmacokinetics, safety and tolerability of KD025 and
KD025 metabolites in subjects with mild, moderate or severe hepatic impairment compared to
healthy subjects with normal hepatic function.